Overview of Cannabinoid Medicine: From MS Spasticity to Epilepsy to Addiction Treatment
A broad review of cannabinoid pharmacology found therapeutic potential across multiple conditions including MS spasticity, neuropathic pain, nausea, epilepsy, psychosis, and addiction.
Quick Facts
What This Study Found
The review covers the endocannabinoid system's role in immune response, appetite, cognition, emotion, perception, motor coordination, body temperature, sleep, and bone metabolism. THC and CBD have contrasting pharmacological profiles: THC activates cannabinoid receptors producing both therapeutic and intoxicating effects, while CBD modulates the system without intoxication.
The strongest clinical evidence existed for MS spasticity (Sativex), chronic neuropathic pain, and chemotherapy-induced nausea and vomiting. Emerging areas of research included epilepsy, psychosis, addiction, and metabolic disorders.
The review also considers the risks of drugs that inhibit the endocannabinoid system (like the withdrawn weight-loss drug rimonabant, which caused serious psychiatric side effects), demonstrating that both enhancing and suppressing this system carries therapeutic potential and risk.
Key Numbers
Indications reviewed: MS spasticity, neuropathic pain, nausea/vomiting, appetite/weight (cancer/AIDS), psychosis, epilepsy, addiction, metabolic disorders. Key contrast: THC (intoxicating, receptor agonist) vs. CBD (non-intoxicating, modulatory).
How They Did This
This is a narrative review of clinical research on cannabinoid medicines. It covers the pharmacology of THC and CBD, the endocannabinoid system, and clinical evidence across multiple indications. The review was published alongside related papers on cannabis cultivation and pharmaceutical development.
Why This Research Matters
This review provides a comprehensive overview of the state of cannabinoid medicine as of 2014, capturing a critical inflection point when cannabis-based medicines were transitioning from fringe therapies to regulated pharmaceuticals. It frames the therapeutic landscape that would continue to develop over the following decade.
The Bigger Picture
The endocannabinoid system's involvement in so many physiological processes explains both the broad therapeutic potential and the broad side effect profile of cannabinoid medicines. The contrast between THC and CBD pharmacology has become the central organizing principle for cannabinoid medicine development.
What This Study Doesn't Tell Us
This is a narrative review that predates many of the definitive clinical trials in cannabinoid medicine. The evidence base was still developing for most indications. The review was published in a journal focused on drug testing, and the selection of evidence may not be comprehensive.
Questions This Raises
- ?Which indications will produce the strongest clinical evidence for cannabinoid medicines?
- ?Can the therapeutic effects of THC be achieved without its intoxicating properties?
- ?What new cannabinoid compounds beyond THC and CBD will prove therapeutically useful?
Trust & Context
- Key Stat:
- ECS modulates immune response, appetite, cognition, emotion, motor coordination, sleep, and bone metabolism
- Evidence Grade:
- This is a narrative review covering a wide range of indications with varying levels of evidence, from well-established (MS spasticity) to highly preliminary (metabolic disorders).
- Study Age:
- Published in 2014. Significant clinical advances have occurred since, including FDA approval of Epidiolex for epilepsy in 2018.
- Original Title:
- Therapeutic potential of cannabinoid medicines.
- Published In:
- Drug testing and analysis, 6(1-2), 24-30 (2014)
- Authors:
- Robson, P J(2)
- Database ID:
- RTHC-00858
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is the difference between THC and CBD?
THC is the intoxicating compound that produces the "high" and directly activates cannabinoid receptors. CBD is non-intoxicating and modulates the endocannabinoid system indirectly. They have different and sometimes opposing therapeutic profiles.
What happened with rimonabant?
Rimonabant was a CB1 receptor blocker developed as a weight-loss drug. It was withdrawn from the market after causing serious psychiatric side effects including depression and suicidal ideation, demonstrating the risks of suppressing the endocannabinoid system.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00858APA
Robson, P J. (2014). Therapeutic potential of cannabinoid medicines.. Drug testing and analysis, 6(1-2), 24-30. https://doi.org/10.1002/dta.1529
MLA
Robson, P J. "Therapeutic potential of cannabinoid medicines.." Drug testing and analysis, 2014. https://doi.org/10.1002/dta.1529
RethinkTHC
RethinkTHC Research Database. "Therapeutic potential of cannabinoid medicines." RTHC-00858. Retrieved from https://rethinkthc.com/research/robson-2014-therapeutic-potential-of-cannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.